EEX vs ABUS Comparison

Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States, with operations in the United Kingdom (U.K.), France, and other markets. The company is engaged in three complementary business lines: Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division provides B2B e-commerce and digital merchandising solutions to manufacturers and retailers. Emerald's key revenue is derived from the Connections business, its only reportable segment.

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.